• Contact Email
  • Phone Number (617) 843-5032

Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy. Unum is seeking partners interested in using the ACTR technology to arm proprietary tumor-specific antibodies with a T-cell to improve their therapeutic potential. The company is headquartered in Cambridge, MA.

Read More

Lists Featuring This Company

Venture Capital Funded Companies (Top 10K)
9,726 Number of Organizations • $1.5T Total Funding Amount • 89,804 Number of Investors
United States Therapeutics Companies
2,134 Number of Organizations • $77B Total Funding Amount • 5,528 Number of Investors
Health Care Public Companies
2,112 Number of Organizations • $126.4B Total Funding Amount • 3,857 Number of Investors
Biotechnology Companies that Exited
4,545 Number of Organizations • $223.9B Total Funding Amount • 9,915 Number of Investors